A Phase 2 interventional study of INGAP-Peptide and INGAP-Peptide in Diabetes Mellitus, Non-Insulin-Dependent, sponsored by Exsulin Corporation. Completed at 17 sites in United States. Open to participants aged 35 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-07-11.
Sponsored by Exsulin Corporation · Phase 2, Interventional, and Treatment
Insulin is a chemical that the body needs in order to use or store sugar. It is made by a type of cell called a beta cell which resides in an organ known as the pancreas. Type 2 diabetes is a disease where the beta cells are unable to meet a person's insulin needs. Sugar levels rise in the blood as a result. INGAP-Peptide is being tested to attempt to create new beta cells in the pancreas, and to improve the ability to produce insulin in type 2 diabetic patients.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 126 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Exsulin Corporation is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria
1.5 mL SC injection, once daily for 90 days
Drug: placebo
1.5 mL SC injection, once daily for 90 days
Drug: INGAP-Peptide
1.5 mL SC injection, once daily for 90 days
Drug: INGAP-Peptide
1.5 mL, once daily, self-administered SC injection for 90 days
1.5 mL, once daily, self-administered SC injection for 90 days
1.5 mL, once daily, self-administered SC injection for 90 days
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.